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Abstract 
 
This report describes the production of ERM®-AD456/IFCC, which is a material certified for the catalytic activity concentration of alpha-amylase. This 
material was produced following ISO 17034:2016 [ ] and is certified in accordance with ISO Guide 35:2017. 
The starting material was pancreatic alpha-amylase purified from human tissue. The enzyme was diluted in a buffered solution which was filled into glass 
vials and lyophilised.   
Between unit-homogeneity was quantified and stability during dispatch and storage were assessed in accordance with ISO Guide 35:2017.  
The material was characterised by an interlaboratory comparison of laboratories of demonstrated competence and adhering to ISO/IEC 17025.  
Uncertainties of the certified values were calculated in accordance with the Guide to the Expression of Uncertainty in Measurement (GUM) [ ] and include 
uncertainties related to possible inhomogeneity, instability and characterisation. 
The material is intended for the assessment of method performance of the primary reference measurement procedure (PRMP) for the catalytic activity 
concentration of alpha–amylase at 37 °C established by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). In addition the 
material can also be used as trueness control or external quality control material for routine measurement systems if commutability has been proven for 
the assay concerned. As with any reference material, it can be used for establishing control charts or in validation studies. The CRM is available in glass 
vials containing lyophilised material from 1 mL of alpha-amylase solution which were sealed under an atmosphere of nitrogen. The minimum amount of 
sample to be used is 5 µL after reconstitution of the whole content of 1 vial in 1 mL. 
 
 
 
 
 
  
 
 
 
 
 
CERTIFICATION REPORT 
 
 
The certification certification of the catalytic activity 
concentration of alpha-amylase in ERM®-AD456/IFCC 
 
 
 
 
 
Liesbet Deprez, Ingrid Zegers, Heinz Schimmel, Stefanie Trapmann 
 
 
 
 
 
 
European Commission, Joint Research Centre 
Directorate F – Health, Consumers and Reference Materials 
Geel, Belgium 
 
 
 
 
 
 
 Disclaimer 
 
Certain commercial equipment, instruments, and materials are identified in this paper to specify adequately the 
experimental procedure. In no case does such identification imply recommendation or endorsement by the 
European Commission, nor does it imply that the material or equipment is necessarily the best available for the 
purpose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
Summary 
This report describes the production of ERM®-AD456/IFCC, which is a material certified for 
the catalytic activity concentration of alpha-amylase. This material was produced following 
ISO 17034:2016 [1] and is certified in accordance with ISO Guide 35:2017 [2]. 
The starting material was pancreatic alpha-amylase purified from human tissue. The enzyme 
was diluted in a buffered solution which was filled into glass vials and lyophilised.   
Between unit-homogeneity was quantified and stability during dispatch and storage were 
assessed in accordance with ISO Guide 35:2017 [2].  
The material was characterised by an interlaboratory comparison of laboratories of 
demonstrated competence and adhering to ISO/IEC 17025 [3].  
Uncertainties of the certified values were calculated in accordance with the Guide to the 
Expression of Uncertainty in Measurement (GUM) [4] and include uncertainties related to 
possible inhomogeneity, instability and characterisation. 
The material is intended for the assessment of method performance of the primary reference 
measurement procedure (PRMP) for the catalytic activity concentration of alpha–amylase at 
37 °C established by the International Federation of Clinical Chemistry and Laboratory 
Medicine (IFCC) [5,6]. In addition the material can also be used as trueness control or 
external quality control material for routine measurement systems if commutability has been 
proven for the assay concerned. As with any reference material, it can be used for 
establishing control charts or in validation studies. The CRM is available in glass vials 
containing lyophilised material from 1 mL of alpha-amylase solution which were sealed under 
an atmosphere of nitrogen. The minimum amount of sample to be used is 5 µL after 
reconstitution of the whole content of 1 vial in 1 mL. 
The following values were assigned: 
 
 
Catalytic activity concentration 
Certified value 2) Uncertainty 3) 
Alpha-amylase1)  274 U/L 
4.58 µkat/L 
7 U/L 
0.12 µkat/L 
1)
 Catalytic activity concentration of alpha-amylase in the reconstituted material, as obtained by the PRMP for the 
measurement of catalytic activity concentration of alpha-amylase at 37 °C from the IFCC. 
2)
 Certified values are values that fulfil the highest standards of accuracy and represent the unweighted mean value of 
the means of accepted sets of data, each set being obtained in a different laboratory. The certified values and their 
uncertainty are traceable to the International System of units (SI). Values were converted from U/L into µkat/L by 
multiplication with the factor f = 0.01667.  
3)
 The uncertainty is the expanded uncertainty of the certified value with a coverage factor k = 2 corresponding to a 
level of confidence of about 95 % estimated in accordance with ISO/IEC Guide 98-3, Guide to the Expression of 
Uncertainty in Measurement (GUM:1995), ISO, 2008. " 
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Glossary 
ANOVA  Analysis of variance 
b Slope in the equation of linear regression y = a + bx 
BCR® One of the trademarks of CRMs owned by the European Commission; 
formerly Community Bureau of Reference 
BELAC "Belgische Accrediatie-instelling": national accreditation body of Belgium 
c Mass concentration c = m / V (mass / volume) 
CLSI Clinical and Laboratory Standards Institute 
CNAS China National Accreditation Service 
CRM Certified reference material 
DAkkS "Deutsche Akkreditierungsstelle GmbH": national accreditation body of 
the Federal Republic of Germany 
EC European Commission 
EDTA Ethylenediaminetetraacetic acid 
ENAC "Entidad Nacional de Acreditación" : the national accreditation Body of 
Spain 
ERM® Trademark of European Reference Materials 
EU European Union 
GUM Guide to the Expression of Uncertainty in Measurements 
[ISO/IEC Guide 98-3:2008] 
IFCC International Federation of Clinical Chemistry and Laboratory Medicine 
ISO International Organization for Standardization  
JRC Joint Research Centre of the European Commission 
k Coverage factor 
kat/L Katal per liter 
MSbetween Mean of squares between-unit from an ANOVA 
MSwithin  Mean of squares within-unit from an ANOVA 
n Number of replicates per unit 
N Number of samples (units) analysed 
n.a. Not applicable 
PIPES piperazine-N,N′-bis(2-ethanesulfonic acid) 
PRMP Primary reference measurement procedure 
rel Index denoting relative figures (uncertainties etc.) 
RM Reference material 
RSD Relative standard deviation 
r2 Coefficient of determination of the linear regression 
5 
s Standard deviation 
sbb
 Between-unit standard deviation; an additional index "rel" is added when 
appropriate 
sbetween Standard deviation between groups as obtained from ANOVA; an 
additional index "rel" is added as appropriate 
SI International System of Units 
RM Unit Reference Materials Unit of Directorate F 
RvA "Raad voor Accreditatie" national accreditation body of the Netherlands 
smeas Standard deviation of measurement data; an additional index "rel" is 
added as appropriate 
swithin Standard deviation within groups as obtained from ANOVA; an additional 
index "rel" is added as appropriate 
swb Within-unit standard deviation 
T Temperature 
t Time 
ti Time point for each replicate 
tα, df Critical t-value for a t-test, with a level of confidence of 1-α and df 
degrees of freedom 
tsl Proposed shelf life 
u standard uncertainty  
U expanded uncertainty 
U/L Units per litre 
u*bb  Standard uncertainty related to a maximum between-unit inhomogeneity 
that could be hidden by method repeatability; an additional index "rel" is 
added as appropriate 
ubb Standard uncertainty related to a possible between-unit inhomogeneity;  
an additional index "rel" is added as appropriate 
uc combined standard uncertainty; an additional index "rel" is added as 
appropriate 
uchar  Standard uncertainty of the material characterisation; an additional index 
"rel" is added as appropriate 
uCRM Combined standard uncertainty of the certified value; an additional index 
"rel" is added as appropriate 
UCRM  Expanded uncertainty of the certified value; an additional index "rel" is 
added as appropriate 
u∆ Combined standard uncertainty of measurement result and certified 
value 
ults Standard uncertainty of the long-term stability; an additional index "rel" is 
added as appropriate 
umeas Standard measurement uncertainty 
Umeas Expanded measurement uncertainty 
usts Standard uncertainty of the short-term stability; an additional index "rel" 
6 
is added as appropriate 
ut Standard uncertainty of trueness 
V Volume 
x
 
Arithmetic mean 
refx  Arithmetic mean of results of reference samples 
α significance level 
∆meas Absolute difference between mean measured value and the certified 
value 
νs,meas Degrees of freedom for the determination of the standard deviation smeas 
MSwithinν
 
Degrees of freedom of MSwithin 
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1 Introduction  
1.1 Background 
The protein enzyme alpha-amylase is present in large amounts in the digestive tract where it 
catalyses the hydrolysis of large, alpha-linked polysaccharides (such as starch and glycogen) 
into glucose. The enzyme is mainly secreted by the exocrine pancreas and the salivary 
glands which each produce their specific isoenzyme. In normal circumstances the 
concentration alpha-amylase in the blood is low but lesions in the organs producing the 
enzyme can lead to a large increase. The catalytic activity of (pancreatic) alpha-amylase in 
serum is frequently measured in medical laboratories for detection and diagnosis of acute 
pancreatitis [7] and pancreatic trauma [8].  
The catalytic activity of an enzyme is a property that is measured by the rate of a specified 
chemical reaction under certain experimental conditions. The measurement of this property 
is very important in clinical chemistry, but the standardisation of catalytic activity 
measurements is challenging as a number of parameters influence the enzyme activity (e.g. 
temperature, pH, substrate nature and concentration, activators, inhibitors). Therefore, the 
measurement results are heavily dependent on the measurement procedure used to attain 
them. This led to the development of universally recognised measurement procedures for 
enzymes commonly measured in clinical chemistry, such as the primary reference 
measurement procedures (PRMP) for the measurement of catalytic activity concentrations of 
enzymes at 37 °C from the International Federation of Clinical Chemistry and Laboratory 
Medicine (IFCC) [9]. 
The regulation (EU) 2017/746 of the European Parliament and of the Council on in vitro 
diagnostic medical devices requires traceability of the assigned values of calibrants and 
control materials to reference measurement procedures and/or reference materials of higher 
order. 
In collaboration with members of the IFCC Committee for Reference Systems of Enzymes 
and the IFCC Working Group for Pancreatic Enzymes, the Reference Materials Unit of the 
Joint research Centre (JRC) developed a CRM certified for the catalytic activity concentration 
of alpha-amylase. This material, ERM-AD456/IFCC, is intended to be used as a quality 
control material for the PRMP for the measurement of catalytic activity concentrations of 
alpha-amylase at 37 °C from the IFCC [5,6]. The homogeneity and the stability of ERM-
AD456/IFCC were demonstrated and the certified values were assigned using the PRMP in 
an interlaboratory comparison of expert laboratories. 
1.2 Choice of the material 
Ideally, the material should contain human pancreatic alpha-amylase without significant 
contaminations from human salivary alpha-amylase. The natural presence of salivary alpha-
amylase in human serum underscores the need for an artificial background solution to which 
human pancreatic alpha-amylase is added.  
The starting material was human pancreatic alpha-amylase purified from human tissues by 
Lee Biosolutions (Missouri, USA). The enzyme was provided in lyophilised form and 
solubilised in a buffered solution containing human serum albumin. This starting material and 
the background solution were selected based on the outcome of a commutability study 
carried out by the JRC [10]. The same background solution was also used for the production 
of IRMM/IFCC-456, the previous CRM for alpha-amylase, and the lyophilised material has 
shown to be stable for more than 20 years.   
The aim of the production process was to obtain a material that after reconstituted with 1 mL 
of distilled/deionised water would have a catalytic activity concentration of about 300 U/L.  
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1.3 Design of the CRM project 
A commutability study including five routine measurement procedures was completed to 
select the most appropriate starting material and background solution for the production of  
ERM-AD456/IFCC [10]. 
The material was certified by interlaboratory comparison. Data from expert laboratories using 
the PRMP for the catalytic activity concentration of alpha-amylase at 37 °C from the IFCC [5] 
and adhering to the important procedural details were used [6]. 
The homogeneity and stability of the material were assessed using an automated version of 
the PRMP. The reagent solutions, incubation time, delay time, measurement time and 
spectrometric parameters were according to the official (and manual) version of the PRMP. 
Only the volumes were reduced to suite the instrument’s specifications, however, the volume 
fractions of the sample, of the reagent solution and of the start reagent solution were 
identical to those used in the official PRMP. A correction of evaporation effects during the 
measurement series was applied. This automated version of the PRMP has a high 
throughput (> 120 measurements in 1 run) and the method showed a low average relative 
standard deviation (RSD) during the commutability study [10]. 
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2 Participants 
2.1 Project management and evaluation 
European Commission, Joint Research Centre (JRC), Directorate F – Health, Consumers 
and Reference Materials, Geel, BE  
(accredited to ISO 17034:2016 for production of certified reference materials, BELAC No. 268-RM) 
2.2 Processing  
Biosystems, S.A., Barcelona, ES  
2.3 Homogeneity and stability studies 
*Medizinische Hochschule Hannover, Institut für Klinische Chemie, Kalibrierlaboratorium II, 
Referenzinstitut für Bioanalytik, Hannover, DE  
(measurements under the scope of ISO/IEC 17025:2005 and ISO15195:2003 accreditation, DAkkS No. D-K-
15117-02-00) 
2.4 Characterisation 
The laboratories are listed below in alphabetic order. This order does not necessarily 
correspond to the ranking of the laboratories L01 - L11 described in the Tables of this report. 
*Beijing Aerospace General Hospital, Reference Laboratory, Beijing, CN  
(measurements under the scope of ISO/IEC 17025:2005 and ISO 15195:2003 accreditation, CNAS No. L5536) 
Biosystems, S.A., Barcelona, ES 
*Guangdong Provincial Hospital of Chinese Medicine, Medical Calibration Laboratory, 
Department of Laboratory Medicine, Guangzhou, CN  
(measurements under the scope of ISO/IEC 17025:2005 and ISO 15195:2003 accreditation, CNAS No. L6192) 
LabWest/HagaZiekenhuis, Klinisch Chemisch en Hematologisch Laboratorium, Den Haag, 
NL 
(meaurements under the scope of NEN-EN-ISO 15189:2012 accreditation, RvA No. M027) 
*Maccura Biotechnology Co., Ltd., Reference System Department, Chengdu, CN 
(measurements under the scope of ISO/IEC 17025:2005 and ISO 15195:2003 accreditation, CNAS No. L6172) 
*Medical System Biotechnology Co. Ltd, Reference Laboratory, Ningbo, CN 
(measurements under the scope of ISO/IEC 17025:2005 accreditation, CNAS No.L8377) 
*Medizinische Hochschule Hannover, Institut für Klinische Chemie, Kalibrierlaboratorium II, 
Referenzinstitut für Bioanalytik, Hannover, DE  
(measurements under the scope of ISO/IEC 17025:2005 and ISO15195:2003 accreditation, DAkkS No. D-K-
15117-02-00) 
Ospedale San Raffaele, Servizio di Medicina di Laboratorio, Laboratorio di 
Standardizzazione par la Chimica Clinica, Milano, IT 
Roche Diagnostics GmbH, Penzberg, DE 
*Shanghai Center for Clinical Laboratory, Shanghai, CN   
(measurements under the scope of ISO/IEC 17025:2005 and ISO 15195:2003 accreditation, CNAS No. L6730) 
*Universitat Autònoma de Barcelona, Departament de Bioquímica i de Biologia Molecular, 
Laboratori de Referència d' Enzimologia Clínica, Barcelona, ES  
(measurements under the scope of ISO/IEC 17025:2005 and ISO 15195:2003 accreditation, ENAC No. 
195/LC10.141) 
*Listed in the JCTLM database for reference measurement services 
10 
3 Material processing and process control 
3.1 Origin and purity of the starting material 
Purified alpha-amylase from human pancreatic tissues (product number 120-16) was 
obtained from Lee Biosolutions (Missouri, USA). The enzyme was provided in lyophilised 
form and stored at -20 °C until use. The presence of 4 contaminating enzymes (i.e. alkaline 
phosphatase, aspartate aminotransferase, lipase and protease) was checked by Lee 
Biosolutions and for each contaminating enzyme the relative catalytic activity concentration 
was no more than 0.01 % of the total catalytic activity concentration.  
3.2 Processing and processing control  
The processing of the CRM was done by Biosystems S.A. (Barcelona, ES).  
Based on the catalytic activity concentration of the alpha-amylase powder as determined by 
Lee Biosolutions a calculated amount of the powder was dissolved in a buffered solution to 
obtain a solution with a catalytic activity concentration around 300 U/L. The solution 
contained: 50 mmol/L NaCl, 0.5 mmol/L EDTA, 1.5 mmol/L CaCl2, 30 g/L human albumin, 
and 25 mmol/L PIPES (i.e. piperazine-N,N′-bis(2-ethanesulfonic acid)) at pH 7.  
The solution was filled into colourless glass vials in portions of 1.0 mL during one continuous 
process. The filling order of the vials was reverse in comparison with the numbers indicated 
on the vials; the vial with the highest number was filled first and the vial with number 1 was 
filled at the end. The filling process was controlled by measuring the mass of the filled 
solution in 20 test vials that were placed at regular intervals throughout the filling process 
(see graph in Annex A). The average mass of the filled solutions was 0.995 g and the 
standard deviation (s) was 0.009 g. There was no trend according to the filling sequence at a 
99 % confidence level. 
The filled vials were chilled at -50 °C and then lyophilised. The material in the vials was 
submitted to secondary desiccation at 35 °C for 11 hours. Afterwards the vials were filled 
with pure dry nitrogen and closed using rubber stoppers. Finally the vials were closed with a 
white screw cap and stored at -20 °C. The vials were dispatched on dry ice to the JRC for 
final storage.  
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4 Homogeneity 
A key requirement for any reference material aliquoted into units is equivalence between 
those units. In this respect, it is relevant whether the variation between units is significant 
compared to the uncertainty of the certified value, but it is not relevant if this variation 
between units is significant compared to the analytical variation. Consequently, ISO 
17034:2016 [1] requires RM producers to quantify the between unit variation. This aspect is 
covered in between-unit homogeneity studies. 
The within-unit inhomogeneity does not influence the uncertainty of the certified value when 
the minimum sample intake is respected, but determines the minimum size of an aliquot that 
is representative for the whole unit. Quantification of within-unit inhomogeneity is therefore 
necessary to determine the minimum sample intake. 
4.1 Between-unit homogeneity 
The between-unit homogeneity was evaluated to ensure that the certified value of the CRM 
is valid for all vials of the material, within the stated uncertainty. 
The number of vials selected exceeds the cube root of the total number of vials produced. 
The 20 vials were selected using a random stratified sampling scheme covering the whole 
batch for the between-unit homogeneity test. For this, the batch was divided into 20 groups 
(with a similar number of vials) and one vial was selected randomly from each group.  
Each vial was reconstituted with (1.00 ± 0.01) mL of distilled H2O at 20 – 22 °C and the mass 
of the added H2O was recorded to the nearest 0.1 mg. After reconstitution, four independent 
samples were taken from each selected vial, and analysed by an automated version of the 
PRMP for the catalytic activity concentration of alpha-amylase at 37°C from the IFCC. The 
measurements were performed under repeatability conditions, and in a regular sequence 
eliminating a correlation between the vial number and the position in the measurement 
sequence. A potential analytical drift could therefore be separated from a trend in the filling 
sequence. The obtained measurement results were corrected for the reconstitution volume 
calculated from the recorded mass assuming a water density of 0.997992 g/mL (i.e. the 
density of H2O at 21 °C [11]). The results are shown as a graph in Annex B.  
Regression analyses were performed to evaluate potential trends in the analytical sequence 
as well as trends in the filling sequence. No trends in the filling sequence or the analytical 
sequence were observed at a 95 % confidence level.  
The dataset was assessed for consistency using Grubbs outlier tests at a confidence level of 
99 % on the individual results and on the unit means. No outlying individual results and 
outlying unit means were detected. All the data were retained for statistical analysis. 
Quantification of between-unit inhomogeneity was undertaken by analysis of variance 
(ANOVA), which separates the between-unit variation (sbb) from the within-unit variation (swb). 
The latter is equivalent to the method repeatability if the individual samples were 
representative for the whole vial.  
Evaluation by ANOVA requires mean values per vial, which follow at least a unimodal 
distribution and results for each vial that follow unimodal distributions with approximately the 
same standard deviations. The distribution of the mean values per vial was visually tested 
using histograms and normal probability plots. This inspection confirmed that individual 
results and vial means followed normal distributions.  
It should be noted that sbb,rel and swb,rel are estimates of the true standard deviations and are 
therefore subject to random fluctuations. Therefore, the mean of squares between groups 
(MSbetween) can be smaller than the mean of squares within groups (MSwithin), resulting in 
negative arguments under the square root used for the estimation of the between-unit 
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variation, whereas the true variation cannot be lower than zero. In this case, u*bb, the 
maximum inhomogeneity that could be hidden by method repeatability, was calculated as 
described by Linsinger et al. [12]. u*bb is comparable to the limit of detection of an analytical 
method, yielding the maximum inhomogeneity that might be undetected by the given study 
setup.  
Method repeatability (swb,rel), between–unit standard deviation (sbb,rel) and u*bb,rel were 
calculated as:  
y 
within
rel,wb
MS
s =
 Equation 1 
y
n
MSMS
s
withinbetween
rel,bb
−
=  Equation 2 
y
νn
MS
u
MSwithin
within
*
rel,bb
4
2
=  Equation 3 
MSwithin mean of squares within-unit from an ANOVA  
MSbetween mean of squares between-unit from an ANOVA  
y  mean of all results of the homogeneity study  
n mean number of replicates per unit  
MSwithinν  degrees of freedom of MSwithin  
 
The results of the evaluation of the between-unit variation are summarised in Table 1. The 
resulting value from the above equation was converted into a relative uncertainty. 
 
Table 1: Results of the homogeneity study 
ERM-AD456/IFCC 
swb,rel  
[%]
 
sbb,rel  
[%]
 
u*bb,rel 
[%] 
ubb,rel 
[%] 
Catalytic activity concentration of 
alpha-amylase 
1.16 0.94 0.25 0.94 
  
The homogeneity study showed no outlying unit means or trends in the filling sequence. 
Therefore the between-unit standard deviation can be used as estimate of ubb. As u*bb sets 
the limits of the study to detect inhomogeneity, the larger value of sbb and u*bb is adopted as 
uncertainty contribution to account for potential inhomogeneity. 
4.2 Within-unit homogeneity and minimum sample intake 
The within-unit homogeneity is closely correlated to the minimum sample intake. The 
minimum sample intake is the minimum amount of sample that is representative for the 
whole unit and thus should be used in an analysis. Using sample sizes equal or above the 
minimum sample intake guarantees the certified values within their stated uncertainty.  
Homogeneity and stability experiments were performed using a 5 µL sample intake. This 
sample intake gives acceptable repeatability, demonstrating that the within-unit 
inhomogeneity no longer contributes to analytical variation at this sample intake.  
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5 Stability 
Time, temperature, light (including ultraviolet radiation) and water content were regarded as 
the most relevant influences on the stability of the materials. The influence of ultraviolet or 
visible light was minimised by storing the material in the dark and dispatched in boxes, thus 
removing any possibility of degradation by light. The water content was reduced by freeze-
drying to obtain a stable material. Therefore, only the influences of time and temperature 
needed to be investigated. 
Stability testing is necessary to establish the conditions for storage (long-term stability) as 
well as the conditions for dispatch of the materials to the customers (short-term stability). 
During transport, especially in summer time, temperatures up to 60 °C can be reached and 
stability under these conditions must be demonstrated, if the samples are to be transported 
without any cooling. 
The stability studies were carried out using an isochronous design [13]. In this approach, 
samples were stored for a particular length of time at different temperature conditions. 
Afterwards, the samples were moved to conditions where further degradation can be 
assumed to be negligible (reference conditions). At the end of the isochronous storage, the 
samples were analysed simultaneously under repeatability conditions. Analysis of the 
material (after various exposure times and temperatures) under repeatability conditions 
greatly improves the sensitivity of the stability tests.  
5.1 Short-term stability study 
For the short-term stability study, samples were stored at -20 °C, 4 °C, and 18 °C for 0, 1, 2 
and 4 weeks (at each temperature). The reference temperature was set to -70 °C. Four vials 
per storage time were selected using a random stratified sampling scheme.  
After reconstitution, 3 samples were taken from each vial and measured by the automated 
version of the PRMP for the catalytic activity concentration of alpha-amylase. The 
measurements were performed under repeatability conditions, and in a regular sequence 
eliminating a correlation between the storage time and the position in the measurement 
sequence. A potential analytical drift could therefore be differentiated from a trend over 
storage time. The obtained measurement results were corrected for the reconstitution 
volume assuming a temperature of 21 °C. 
The data were evaluated individually for each temperature. The results were screened for 
outliers using the single and double Grubbs test with a confidence level of 99 %. No outlying 
individual results were found.  
The data were evaluated against storage time, and regression lines of catalytic activity 
concentration of alpha-amylase versus time were calculated, to test for potential 
increases/decreases of the catalytic activity concentration due to shipping conditions. The 
slopes of the regression lines were tested for statistical significance. None of the trends was 
statistically significant at a 95 % confidence level for any of the temperatures.  
The results of the measurements are shown in Annex C.  
The material shall be shipped under cooled conditions, to avoid exposure to higher 
temperatures than those tested. 
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5.2 Long-term stability study 
For the long-term stability study, samples were stored at -20 °C for 0, 4, 8 and 12 months. 
The reference temperature was set to -70 °C. Five vials per storage time were selected using 
a random stratified sampling scheme. After reconstitution, four samples were taken from 
each vial and measured by an automated version of the PRMP for the catalytic activity 
concentration of alpha-amylase. The measurements were performed under repeatability 
conditions, and in a regular sequence eliminating a correlation between the storage time and 
the position in the measurement sequence. A potential analytical drift could therefore be 
separated from a trend over storage time. The results were corrected for the volume of water 
added during the reconstitution step assuming a temperature of 21 °C.  
Regression analysis was performed to evaluate a potential trend in the analytical sequence. 
A significant (99 % confidence level) trend in the analytical sequence was visible, pointing at 
a changing parameter, e.g. a signal drift in the analytical system. The correction of biases, 
even if they are statistically not significant, was found to combine the smallest uncertainty 
with the highest probability to cover the true value [14]. Correction of trends is therefore 
expected to improve the sensitivity of the subsequent statistical analysis through a reduction 
in analytical variation without masking a potential trend over storage time. As the analytical 
sequence and the storage time were not correlated, the significant trend was corrected as 
shown below:  
ibxx icorri ⋅−=_  Equation 4 
b   slope of the linear regression  
i   position of the result in the analytical sequence 
The trend-corrected dataset was screened for outliers using the single and double Grubbs 
test at a confidence level of 99 %. One outlying individual result was found. As no technical 
reason for the outlier could be found all data were retained for statistical analysis.  
The data were plotted against storage time and linear regression lines of catalytic activity 
concentration versus time were calculated. The slope of the regression lines were tested for 
statistical significance (loss/increase due to storage). No significant trend was detected at a 
95 % confidence level. 
The results of the long-term stability measurements are shown in Annex D.  
The material can be stored at -20 °C. 
5.3 Estimation of uncertainties 
Due to the intrinsic variation of measurement results, no study can entirely rule out 
degradation of materials, even in the absence of statistically significant trends. It is therefore 
necessary to quantify the potential degradation that could be hidden by the method 
repeatability, i.e. to estimate the uncertainty of stability. This means that, even under ideal 
conditions, the outcome of a stability study can only be that there is no detectable 
degradation within an uncertainty to be estimated.  
15 
The uncertainties of stability during dispatch and storage were estimated, as described in 
[15]. In this approach, the uncertainty of the linear regression line with a slope of zero was 
calculated. The uncertainty contributions usts and ults were calculated as the product of the 
chosen transport time/shelf life and the uncertainty of the regression lines as: 
( ) tti
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 Equation 6 
 relative standard deviation of all results of the stability study   time elapsed at time point i  ̅ mean of all      chosen transport time (1 week at 18 ºC)  	 chosen shelf life (12 months at -20 ºC) 
 
The following uncertainties were estimated: 
- usts,rel, the uncertainty of degradation during dispatch. This was estimated from the 
18 °C studies. The uncertainty describes the possible change during a dispatch at 
18 °C lasting for one week. 
- ults,rel, the stability during storage. This uncertainty contribution was estimated from 
the -20 °C studies. The uncertainty contribution describes the possible degradation 
during 12 months storage at -20 °C.  
The results of these evaluations are summarised in Table 2. 
Table 2: Uncertainties of stability during dispatch and storage. usts,rel was calculated for 
a temperature of 18 °C and one week; ults,rel was calculated for a storage temperature 
of -20 °C and 12 months 
ERM-AD456/IFCC usts ,rel [%] 
ults,rel 
[%] 
Catalytic activity concentration of alpha-amylase 0.15 0.47 
 
The material showed no significant degradation for transport at 18 °C or lower, but evidence 
of stability above 18 °C was not obtained. Cooled shipment is therefore necessary to ensure 
that the temperature stays within the tested conditions.  
After the certification study, the material will be included in the JRC's regular stability 
monitoring programme, to control its further stability. 
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6 Characterisation  
The material characterisation is the process of determining the property value of a reference 
material. 
This was based on an interlaboratory comparison of expert laboratories, i.e. the catalytic 
activity concentration of alpha-amylase of the material was determined in different 
laboratories. All participants applied the official (and manual) version PRMP for the 
measurement of catalytic activity concentration of alpha-amylase at 37 °C from the IFCC 
[5,6]. This approach aims at randomisation of laboratory bias, which reduces the combined 
uncertainty. 
6.1 Selection of participants  
Eleven laboratories were selected based on criteria that comprised both technical 
competence and quality management aspects. Each participant was required to operate a 
quality system and to deliver documented evidence of its laboratory proficiency in the field of 
catalytic activity concentration measurements of alpha-amylase using the PRMP. Having a 
formal accreditation was not mandatory, but meeting the requirements of ISO/IEC 17025 was 
obligatory. Where measurements are covered by the scope of accreditation, the accreditation 
number is stated in the list of participants (Section 2). 
Before participating in the characterisation study, the 11 laboratories demonstrated their 
technical competence in a feasibility study. Each laboratory received 3 vials from 2 
independent control materials (6 vials in total) which had to be measured with the PRMP. All 
laboratories were requested to provide detailed information about the calibration of their 
instruments and the purity of the used reagents.  
Based on the provided information it was concluded that each laboratory preformed the 
measurements in compliance with the PRMP as described in [5,6]. The method performance 
of each laboratory was evaluated based on the intermediate precision (repeatability and day-
to-day variation) of the measurement results. For all 11 laboratories this intermediate 
precision was low enough to achieve a precision ≤ 3 % in the final characterisation study.  
The reproducibility of the PRMP among the different laboratories was also evaluated by 
calculating the RSD between the lab means for both test materials and by testing for outlying 
means using the Grubbs test. The RSD between the lab means was ≤ 3.5 % and there were 
no outlying lab means at 99 % confidence level.  
6.2 Study setup  
Each laboratory received five vials of ERM-AD456/IFCC and was requested to provide 15 
measurement results, three per vial. The vials for material characterisation were selected 
using a random stratified sampling scheme covering the whole batch. The measurements on 
the five vials had to be spread over at least two days to ensure intermediate precision 
conditions. Each vial had to be reconstituted with (1.00 ± 0.01) mL of distilled H2O at 
20-22 °C and the mass of the added H2O should be recorded to the nearest 0.1 mg. After 
reconstitution, three independent samples should be taken from each vial and measured 
within 4 hours after reconstitution.  
Laboratories were requested to provide detailed information about the calibration of their 
instruments and the purity of the used reagents to prove compliance with the PRMP as 
described in [5,6]. In addition, laboratories were also requested to give estimations of the 
expanded uncertainties on the mean value of the 15 results. No approach for the estimation 
was prescribed, i.e. top-down and bottom-up were regarded as equally valid procedures.  
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6.3 Methods used 
All laboratories used the PRMP for the catalytic activity concentration of alpha-amylase at 
37 °C from the IFCC [5,6].  
6.4 Evaluation of results 
The characterisation study resulted in 11 datasets and an estimate of the expanded 
uncertainty was provided for 9 of these datasets. Ten laboratories provided measurement 
results that were not corrected for the reconstitution volume. The masses recorded during 
the reconstitution step were used to correct these results assuming a temperature of 21 °C, 
unless another temperature was reported by the laboratory. All individual results of the 
participants are displayed in tabular and graphical form in Annex E.  
6.4.1 Technical evaluation 
The obtained data were first checked for compliance with the requested analysis protocol 
and for their validity based on technical reasons. The following criteria were considered 
during the evaluation:  
- compliance with the PRMP: proper calibration of relevant instruments (pH meter, 
balance, spectrophotometer, thermometers and pipettes) and use of reagents with 
the highest purity. 
- compliance with the analysis protocol: measurements performed on at least two 
days. 
- method performance: repeatability ( i.e. within-vial standard deviation ≤ 1.5 %)  
Based on the above criteria, none of the datasets were rejected as not technically valid.  
6.4.2 Statistical evaluation 
The statistical evaluation of the datasets was based on the mean result obtained for each 
vial. The statistical evaluation of the datasets was based on the mean result obtained for 
each vial. The datasets accepted based on technical reasons were tested for normality of 
dataset means using kurtosis/skewness tests and normal probability plots and were tested 
for outlying means using the Grubbs test and using the Cochran test for outlying standard 
deviations, (both at a 99 % confidence level). Standard deviations within (swithin) and between 
(sbetween) laboratories were calculated using one-way ANOVA. The results of these 
evaluations are shown in Table 3. 
Table 3: Statistical evaluation of the technically accepted datasets for ERM-
AD456/IFCC. p: number of technically valid datasets 
ERM-
AD456/IFCC 
p Outliers Normally 
distributed 
Statistical parameters  
Means Variances Mean 
[U/L] 
s 
[U/L] 
sbetween 
[U/L] 
swithin 
[U/L] 
Catalytic 
activity 
concentration of 
alpha-amylase 
11 None None yes 274.45 5.88 5.74 2.80 
 
The laboratory means follow a normal distribution. There are no outlying lab means and 
variances. The datasets are therefore consistent and the mean of laboratory means is a 
good estimate of the true value. The standard deviation between laboratories is considerably 
larger than the standard deviation within laboratories, showing that confidence intervals of 
replicate measurements are unsuitable as estimate of measurement uncertainty. 
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The uncertainty related to the characterisation is estimated as the standard error of the mean 
of laboratory means (Table 4). 
 
Table 4: Uncertainty of characterisation for ERM-AD456/IFCC 
ERM-AD456/IFCC p Mean 
[U/L] 
s 
[U/L] 
uchar,rel 
[%] 
Catalytic activity concentration of alpha-amylase 11 274.45 5.88 0.65 
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7 Value Assignment 
A certified value for the catalytic activity concentration of alpha-amylase was assigned to 
ERM-AD456/IFCC. 
Certified values are values that fulfil the highest standards of accuracy. Procedures at the 
JRC, Directorate F require generally pooling of not less than 6 datasets to assign certified 
values. Full uncertainty budgets in accordance with the 'Guide to the Expression of 
Uncertainty in Measurement' [4] were established.  
7.1 Certified values and their uncertainties 
The unweighted mean of the means of the accepted datasets as shown in Table 4 was 
assigned as certified value.  
The assigned uncertainty consists of uncertainties relating to characterisation, uchar (Section 
6), potential between-unit inhomogeneity, ubb (Section 4.1), and potential degradation during 
transport, usts, and long-term storage, ults (Section 5). The different contributions were 
combined to estimate the relative expanded uncertainty of the certified value (UCRM, rel) with a 
coverage factor k given as:  

, = 	 ∙ 	, + 		, + 		, + ,  Equation 7 
- uchar was estimated as described in Section 6  
- ubb was estimated as described in Section 4.1 
- usts and ults were estimated as described in Section 5.3 
 
Because of the sufficient numbers of the degrees of freedom of the different uncertainty 
contributions, a coverage factor k of 2 was applied, to obtain the expanded uncertainties. The 
certified value expressed in U/L and its uncertainty is summarised in Table 5. 
 
Table 5: Certified value expressed in U/L and its uncertainty for ERM-AD456/IFCC 
 
Certified value 
[U/L] 
uchar,rel 
[%] 
ubb,rel  
[%] 
usts,rel  
[%] 
ults,rel 
[%] 
UCRM, rel 1) 
[%] 
UCRM 1) 
[U/L] 
Catalytic activity 
of alpha-amylase 274 0.65 0.94 0.15 0.47 2.48 7 
 
1)
 Expanded (k = 2) and rounded uncertainty. 
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8 Metrological traceability and commutability 
8.1 Metrological traceability  
Identity 
The catalytic activity concentration of alpha-amylase is a method-defined measurand and 
can only be obtained by following the procedure specified in the PRMP at 37 °C of the IFCC 
[5,6]. Adherence to this procedure was confirmed by the detailed information on instrument 
calibration and reagent purity provided by the participating laboratories. The measurand is 
therefore operationally defined by the PRMP. 
Quantity value 
Traceability of the obtained results is based on the traceability of all relevant input factors. 
Instruments in individual laboratories were verified and calibrated with tools ensuring 
traceability to the International System of units (SI). Consistency in the interlaboratory 
comparison supports the assumption that all relevant input factors were covered. As the 
assigned values are combinations of agreeing results individually traceable to the SI, the 
assigned quantity values themselves are traceable to the SI as well. 
8.2 Commutability 
Many measurement procedures include one or more steps which select specific (or specific 
groups of) analytes from the sample for the subsequent whole measurement process. Often 
the complete identity of these 'intermediate analytes' is not fully known or taken into account. 
Therefore, it is difficult to mimic all analytically relevant properties of real samples within a 
CRM. The degree of equivalence in the analytical behaviour of real samples and a CRM with 
respect to various measurement procedures (methods) is summarised in a concept called 
'commutability of a reference material'. There are various definitions that define this concept. 
For instance, the CLSI Guideline C30-A [16] recommends the use of the following definition 
for the term commutability: 
"The equivalence of the mathematical relationships among the results of different 
measurement procedures for an RM and for representative samples of the type intended 
to be measured." 
The commutability of a CRM defines its fitness for use and is therefore a crucial 
characteristic when applying different measurement methods. When the commutability of a 
CRM is not established, the results from routinely used methods cannot be legitimately 
compared with the certified value to determine whether a bias does not exist in calibration, 
nor can the CRM be used as a calibrant. For instance, CRMs intended to be used to 
establish or verify metrological traceability of routine clinical measurement procedures must 
be commutable for the routine clinical measurement procedures for which they are intended 
to be used. 
A commutability study was carried out in which a trial batch of the starting material for ERM-
AD456/IFCC was compared with 30 frozen serum pools [10]. Each serum pool was prepared 
from about 10 single donation sera to obtain sufficiently large volumes which could be 
aliquoted and distributed to the participating laboratories. Frozen serum pools have been 
used in EQA schemes for the catalytic concentration of α-amylase before and it has been 
shown that they behave like single donation sera for several routine methods.  
The serum pools and the trial batch of ERM-AD456/IFCC were measured with five different 
routine clinical measurement procedures and the automated version of the PRMP for the 
catalytic activity concentration of alpha-amylase from the IFCC. The list of the routine clinical 
measurement procedures included in the study is available in Annex F. Two different 
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approaches were used to assess the commutability: a linear regression analysis with a 95 % 
prediction interval as described in CLSI EP30-A [16] and a difference in bias analysis as 
described in the recommendations of the IFCC Working Group on Commutability [17]. The 
commutability criterion for the difference in bias analysis was set at 3.7 %. The results of this 
study are shown in Annex F.  
The trial batch of ERM-AD456/IFCC had a good commutability profile for all tested routine 
methods with the same substrate as the PRMP. The applied commutability criterion of 3.7 % 
in this study is sufficient to prove that ERM-AD456/IFCC is suitable as trueness control or as 
external quality control material for the relevant routine methods. A CRM intended to be used 
in the calibration hierarchy of routine measurement systems might require a stricter 
commutability criterion and smaller uncertainty on the commutability assessments than 
obtained in this study. In case the customer intends to use ERM-AD456/IFCC as a calibrant 
for a routine measurement procedure it is recommended to perform an additional 
commutability study with a stricter commutability criterion and more replicate measurements 
for ERM-AD456/IFCC (>6). 
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9 Instructions for use 
9.1 Safety information 
The usual laboratory safety measures apply. The human pancreatic alpha-amylase and the 
human serum albumin used in the production of the material have been tested and found 
negative for Hepatitis B surface antigen, HIV 1&2, and Hepatitis C antibodies. However, the 
product must be handled with adequate care as any material of human origin. It is intended 
for in vitro analysis only.  
9.2 Storage conditions 
The materials should be stored at (-20 ± 5) °C in the dark. After reconstitution, the material 
must be used within four hours.  
Please note that the European Commission cannot be held responsible for changes that 
happen during storage of the material at the customer's premises, especially for opened 
vials. 
9.3 Reconstitution 
To make it ready for use, the material has to be reconstituted according to the following 
procedure:  
1. Remove the vial from the freezer and let equilibrate to room temperature (20-25 °C).  
2. Tap the vertically positioned vial gently to ensure that the lyophilised material is at the 
bottom of the vial. Remove the screw cap.  
3. Weigh the vial together with the rubber stopper and record the mass to the nearest 
0.1 mg (i.e. m1). 
4. Carefully lift the rubber stopper, avoiding the loss of lyophilised material. 
5. Reconstitute with (1.00 ± 0.01) mL distilled water (20-22 °C) and carefully close the vial 
again with the rubber stopper. 
6. Weigh the vial after adding the water and record the weight to the nearest 0.1 mg (i.e. 
m2). Calculate the mass of the water added during the reconstitution (mH2O) by 
subtracting m1 from m2. Use this mH2O to calculate volume of the added water (vH2O) 
taking into account the temperature dependent density. 
7 The catalytic concentration of alpha-amylase in the solution, corrected for the 
reconstitution volume, can be obtained by multiplying the certified value with 
vintended/vH2O with vintended the volume intended to be added (1.0000 mL) 
8. Dissolve the lyophilised material by gently swirling and carefully invert the vial at least 
five times. Allow to stand at room temperature for 10 minutes.  
9. It is recommended to store the vials cold (2-8 °C) if not measured directly. Carefully 
invert the vial five times just before starting the measurements. 
10. The catalytic activity concentration of amylase must be measured within 4 hours 
following the reconstitution. 
9.4 Minimum sample intake 
The minimum sample intake representative for the catalytic activity concentration of alpha-
amylase in ERM-AD456/IFCC is 5 µL as this was the sample intake for the homogeneity and 
stability studies.  
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9.5 Use of the certified value 
The main purpose of the material is to assess method performance of the PRMP for the 
catalytic activity concentration of alpha-amylase at 37 °C from the IFCC [5,6]. In addition the 
material can also be used as trueness control or external quality control material for routine 
measurement systems if commutability has been proven for the assay concerned. As any 
reference material, it can be used for establishing control charts or in validation studies. 
Use as a calibrant 
It is not recommended to use this material as calibrant. If used nevertheless, the uncertainty 
of the certified value shall be taken into account in the estimation of the measurement 
uncertainty. When the material is used as a calibrant in a routine measurement procedure 
the commutability should be verified for the assay concerned.  
Comparing an analytical result with the certified value 
A result is unbiased if the combined standard uncertainty of measurement and certified value 
covers the difference between the certified value and the measurement result (see also ERM 
Application Note 1, https://crm.jrc.ec.europa.eu/e/132/User-support-Application-Notes [18].  
When assessing the method performance, the measured values of the CRMs are compared 
with the certified values. The procedure is summarised here:  
- Calculate the absolute difference between mean measured value and the certified 
value (∆meas). 
- Combine the measurement uncertainty (umeas) with the uncertainty of the  
certified value (uCRM): 22 CRMmeas uuu +=∆  
- Calculate the expanded uncertainty (U∆) from the combined uncertainty (u∆,) using an 
appropriate coverage factor, corresponding to a level of confidence of approximately 
95 % 
- If ∆meas ≤ U∆ then no significant difference exists between the measurement result 
and the certified value, at a confidence level of approximately 95 %. 
 
Use in quality control charts 
The materials can be used for quality control charts. Using CRMs for quality control charts 
has the added value that a trueness assessment is built into the chart. 
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Annexes 
Annex A: Results from the processing control measurements 
 
Figure A1: Weighing results of the mass of the filled solution in 20 test vials placed at regular 
intervals throughout the filling process of ERM-AD456/IFCC.  
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Annex B: Results of the homogeneity measurements 
 
Figure B1: Homogeneity data of the catalytic activity concentration of alpha-amylase in 
ERM-AD456/IFCC as measured with an automated version of the PRMP from the IFCC. 
Shown are the averages per vial number and their 95 % confidence interval based on the 
within-group standard deviation as derived from a one-way ANOVA of all data grouped by 
vial number.  
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Annex C: Results of the short-term stability measurements 
   
 
Figure C: Isochronous short-term stability measurements of the catalytic activity 
concentration of alpha-amylase stored at 18 °C in A, 4 °C in B and -20 °C in C. 
Measurements were performed with an automated version of the PRMP from the IFCC. 
Shown are the averages per time point and their 95 % confidence interval based on the 
within-group standard deviation as derived from a one-way ANOVA of all data grouped by 
time point.  
A 
B 
C 
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Annex D: Results of the long-term stability measurements 
 
Figure D: Isochronous long-term stability measurements of the catalytic activity 
concentration of alpha-amylase stored at -20 °C. Measurements were performed with an 
automated version of the PRMP from the IFCC. Shown are the averages per time point and 
their 95 % confidence interval based on the within-group standard deviation as derived from 
a one-way ANOVA of all data grouped by time point. 
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Annex E: Results of the characterisation measurements 
Table E1: All accepted individual results, the mean laboratory values and the expanded uncertainty (when provided by the laboratories) for the 
catalytic activity concentration of alpha-amylase in ERM-AD456/IFCC measured with the PRMP of the IFCC. For all but one laboratory 
(indicated by an asterisk) the reported results were not yet corrected for the reconstitution volume. These results were corrected assuming a 
H2O temperature of 21 °C, unless another temperature was reported.  
Lab code replicate Vial 1 [U/L] Vial 2 [U/L] Vial 3 [U/L] Vial 4 [U/L] Vial 5 [U/L] Mean [U/L] 
Expanded uncertainty 
[U/L] 
L1 
1 266.9 269.0 265.7 266.5 264.7 
266.4 5.9 2 265.8 268.3 267.2 266.4 260.4 
3 268.2 268.2 272.2 265.0 261.4 
L2 
1 263.1 262.2 264.8 263.5 264.4 
265.2 Not provided 2 259.0 269.1 261.4 271.7 265.2 
3 263.6 267.3 263.2 268.7 270.5 
L3* 
1 267.5 267.5 270.5 266.5 269.9 
268.3 7.2 2 272.1 265.8 267.5 268.7 269.6 
3 269.3 267.0 267.4 265.3 269.5 
L4 
1 268.8 266.5 271.7 270.9 268.3 
270.6 11.4 2 269.8 268.9 274.7 274.0 269.2 
3 271.6 268.3 273.5 274.0 268.3 
L5 
1 282.5 277.3 282.3 279.4 271.9 
278.3 Not provided 2 278.3 279.4 282.6 274.6 271.9 
3 282.4 279.7 283.2 274.9 273.8 
L6 
1 283.0 283.4 276.7 281.4 280.8 
281.3 8.5 2 284.2 281.6 277.9 282.2 281.2 
3 283.7 282.5 277.3 282.8 280.7 
L7 
1 275.4 281.0 271.6 281.3 280.1 
277.8 6.7 2 275.1 278.8 269.9 282.6 279.9 
3 276.9 280.0 270.3 282.4 282.0 
L8 
1 278.5 270.6 270.9 273.9 275.0 
274.0 9.2 2 276.9 272.5 271.4 274.7 275.5 
3 278.0 271.4 270.9 274.7 274.7 
L9 
1 283.0 279.3 276.3 276.5 281.3 
279.6 5.9 2 282.5 278.0 278.1 277.1 281.3 
3 283.5 279.0 278.7 277.4 282.2 
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Table E1 (continued) 
Lab code replicate Vial 1[U/L] Vial 2 [U/L] Vial 3 [U/L] Vial 4 [U/L] Vial 5 [U/L] Mean [U/L] 
Expanded uncertainty 
[U/L] 
L10 
1 276.8 277.5 274.7 278.9 273.4 
277.4 6.6 2 278.6 280.6 275.2 279.8 278.6 
3 278.3 279.5 274.3 279.1 276.4 
L11 
1 284.0 276.1 282.3 279.4 283.4 
280.2 9.4 2 283.4 277.0 280.2 280.6 281.2 
3 278.2 281.2 277.8 277.3 280.3 
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Figure E1: Graph showing the laboratory means for the enzymatic activity concentrations of 
alpha-amylase in ERM-AD456/IFCC measured with the PRMP from the IFCC. The error bars 
indicate the expanded measurement uncertainties as reported by the laboratories. Lab 2 and 
Lab 5 did not report the uncertainty associated with their measurement results. The average 
measurement uncertainty of the other participating laboratories was therefore used as an 
estimate of their measurement uncertainty (indicated by an asterisk). The solid black line 
represents the certified value, while the dashed lines represent the expanded uncertainty of 
the certified value. 
*
*
34 
Annex F: Results of the commutability study 
Table F1: The measurement procedures (combination of platforms and reagents) used in the 
commutability study on the trail batch of ERM-AD456/IFCC. There are different substrates 
available to measure the catalytic activity concentration of alpha-amylase including: 2-chloro-
4-nitrophenyl-α-D-maltotrioside (CNPG3) and 4,6-ethylidene(G1)-4-nitrophenyl(G7)-α-
(1→4)–D-maltoheptaoside (EPS). 
 
Method code Platform Reagents or kit used Substrate 
Automated 
version of the 
PRMP  
Konelab 30 i 
(Thermofisher) 
Reagents according to the PRMP 
were used: 
α-glucosidase (Roche diagnostics) 
EPS (Roche diagnostics) 
HEPES (Sigma-Aldrich) 
EPS 
Abbott Architect ci8200 
(Abbott) 
Abbott amylase kit 
Product code 7D58 
CNPG3 
Beckman AU 5800 
(Beckman Coulter) 
Beckman Coulter AMY (alpha 
Amylase IFCC-EPS) 
Product code OSR6182 
EPS 
Biosystems BA-400 
(Biosystems) 
Biosystems alpha-AMYLASE –EPS 
Product code 21534 
EPS 
Roche Cobas c702 
(Roche) 
Roche alpha-amylase EPS ver.2 
Product code 05167027 190 
EPS 
Siemens Advia 2400 
(Siemens) 
ADVIA amylase 
Product code: 03031177 
EPS 
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Table F2: The outcome of the commutability study performed on the trial batch of 
ERM-AD456/IFCC and 30 serum pools. The measurement results of the five routine 
measurement procedures were compared to the measurement results of the automated 
version of the PRMP for the catalytic activity concentration of alpha-amylase from the IFCC. 
Two different statistical approaches were used to assess the commutability: a linear 
regression analysis with 95 % prediction interval as described in CLSI EP30-A (indicated as 
CLSI) and a difference in bias analysis as described in the recommendations of the IFCC 
Working Group on Commutability (indicated as IFCC). The commutability criterion was set at 
3.7 % for the difference in bias analysis.   
 
Statistical analysis 
Method code CLSI IFCC 
Abbott Non-commutable Non commutable 
Beckman Commutable Inconclusive result 
Biosystems Commutable Commutable 
Roche Commutable Commutable 
Siemens Commutable Commutable 
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